医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

NCKU Research Team Reveals Key Mechanism in Lung Cancer

2014年09月25日 PM06:29
このエントリーをはてなブックマークに追加


 

TAINAN, Taiwan

Lung cancer remains one of the most common and malignant cancers worldwide. A Tainan-based research team from National Cheng Kung University (NCKU) has discovered Rab37, a protein in humans which is a critical regulator of vesicle trafficking, has played a vital role in inhibition of cancer metastasis.

The team led by NCKU Distinguished Professor Dr. Yi-Ching Wang from the Department of Pharmacology and Institute of Basic Medical Science, College of Medicine, made major medical breakthrough in tumour treatment, the university revealed at a press conference in Taipei on September 25.

Their research titled “Small GTPase Rab37 targets tissue inhibitor of metalloproteinase 1 for exocytosis and thus suppresses tumour metastasis” has been published in the September issue of Nature Communications.

“What we’ve discovered will help clinicians to better treat patients with lung cancer,” said Dr. Wang.

She noted that Rab-controlled trafficking pathways have been involved in tumorigenesis.

She also explained, Rab37 suppresses metastasis by regulating the exocytosis of tissue inhibitor of metalloproteinase 1 (TIMP1) to repress matrix metalloproteinase 9 (MMP9) and represents a novel prognostic marker for lung cancer.

“We address the metastasis suppressive function of Rab37 using secretomics, cell, animal and clinical analyses,” Dr. Wang added.

The study shows that TIMP1is a novel cargo of Rab37, according to Dr. Wang, and lung cancer patients with metastasis show low Rab37 protein expression coinciding with low TIMP1 in tumours.

Dr. Wang’s team has identified Rab37 as a novel metastasis suppressor Rab that functions through the TIMP1-MMP9 pathway and has significant prognostic power.

CONTACT

National Cheng Kung University
Sonia Chuang, +886-6-275-7575 Ext.
50042
News Center
sonia20@mail.ncku.edu.tw
Fax:
+886-6-238-9919
NCKU news: http://news-en.secr.ncku.edu.tw/bin/home.php

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • GN COS:20分巻くだけで6時間分相当運動のジェル不要「超強力GNEMSベルト」 日本上陸
  • 武田薬品のEXKIVITY™(モボセルチニブ)がEGFRエクソン20挿入変異陽性NSCLC患者向けに特別設計した初の経口治療薬として米国FDAの承認を取得
  • City of Hope and Griffith University Researchers Use Novel Method to Block HIV in Mice
  • バーパックス・ファーマシューティカルズが4000万ドルの普通株式の公募売り出しを完了
  • Virpax® Pharmaceuticals宣布完成公开发行总额4000万美元的普通股